01 mmol/kg of gadopentetate
dimeglumine [Magnevist, n = 21] and 10 mL fixed dose of gadoxetic acid [Primovist, n=6]).
dimeglumine enhanced sagittal and axial (SE) T1W (TR, 450-600 msec; TE, 15-20 msec) images were obtained in all patients of intradural tumours.
Patients in this study were injected with intravenous gadopentetate
dimeglumine during imaging of their elbows.
Moreover, cardiodepressive and hypotensive effects caused by gadopentetate
dimeglumine are dose-dependent [24, 26].
The second was a 363-patient Pan-Asian Phase III trial with 120 Japanese patients, which indicated non-inferiority of gadobutrol-enhanced MR images of the body (breast, heart, abdomen, kidney, pelvis and extremity) to those obtained through the use of gadopentetate
Closely related diagnostic agents are gadobenate dimeglumine (MultiHance), gadodiamide (Omniscan), gadofosveset (Ablavar), gadopentetate
dimeglumine (Magnevist), gadoteridol (Prohance), and gadoversetamide (OptiMARK).
For contrast imaging, T1-weighted FLAIR sequences also were obtained after administration of gadopentetate
Patients were injected with 10 mL of a contrast mixture of diluted (2 mmol/L) gadopentetate
dimeglumine (Magnevist; Bayer Schering Pharma AG, Berlin, Germany) according to the standard protocol.
14] Yirmi emziren kadinda, intravenoz verilen Gadopentetate
dimeglumin maddesinin 24 saat boyunca sutteki oraninin %0.
2 mL/kg gadopentetate
dimeglumine at a concentration of 0.
Patients At higher risk * Patients with CKD 4 and 5 (GFR < 30 ml/min) * Patients on dialysis * Patients with acute kidney insufficiency At lower risk * Patients with CKD 3 (GFR 30 - 59 ml/min) Not at risk of NSF * Patients with stable GFR > 60 ml/min) Highest risk of NSF Gadopentetate
dimeglumine (Magnevist plus generic products) Gadodiamide (Omniscan) Gadoversetamide (Optimark) Recommendations for These agents are CONTRA-INDICATED high-risk group in: * patients with CKD 4 and 5 (GFR <30 ml/min), including those on dialysis * acute renal insufficiency * pregnant women * neonates These agents should be used with CAUTION in: * patients with CKD 3 (GFR 30 - 60 ml/min) * There should be at least 7 days between 2 injections.
Dynamic sequences were obtained before and after a standard 20-mL gadopentetate
dimeglumine (Magnevist, Bayer HealthCare Pharmaceuticals, Inc.